Margin dodolan operasi REGENXBIO Inc. (RGNX)

Logo grafis regenxbio.com (RGNX)

REGENXBIO Inc. (RGNX) integrates ESG principles and ethics into the development of gene therapies. Operating profitability demonstrates the company's dependence on grants and drug trial results. The absence of a stable cash flow leaves the business vulnerable, as development relies on external capital. The value of -120.40 shapes the current metric, determining the resilience of operating profit to market shocks.

regenxbio.com (RGNX): Tingkat bathi operasi saka 04.07.2022 nganti 20.11.2026

Rincian analitis perusahaan REGENXBIO (RGNX)

- rega saham lan konsensus proyeksi valuasi:
Analisis umum perusahaan:REGENXBIO Inc., RGNX
Barang utama regenxbio.com

Licensing the NAV Technology platform creates a foundation for scalability for REGENXBIO Inc. (RGNX) within the gene therapy sector. Operating margin measures the share of profit from core business operations before taxes and interest, reflecting real-world cost management efficiency. This indicator allows analysts to filter out financial noise and assess the internal viability of the model. Analyzing this metric protects investors from capital losses. The dynamics of these processes are reflected in this operating profitability chart.

Perusahaan pesaing

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi